Thus, the finding of a similar interaction between Piezo1 and TRPM4 (Figure 4) opens an attractive possibility of developing novel compounds targeting specifically the Piezo1/TRPM4 interface for treatment of cardiac hypertrophy and possibly other cardiac mechanochannelopathies. The gene discussed is PIEZO1; the disease is cardiac hypertrophy.